Benefit of newer antipsychotics not clear cut

January 2004
PharmacoEconomics & Outcomes News;1/17/2004, Issue 444, p8
Discusses research being done on the use of antipsychotics by patients with schizophrenia. Reference to a study by M. Percudani et al, published in the November 2003 issue of the "Journal of Clinical Psychiatry"; Effectiveness of atypical antipsychotics in medicating schizophrenics compared to conventional antipsychotics; Cost effectiveness of conventional antipsychotics.


Related Articles

  • The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. Selva-Vera, Gabriel; Balanzá-Martínez, Vicent; Salazar-Fraile, José; Sánchez-Moreno, José; Martinez-Aran, Anabel; Correa, Patricia; Vieta, Eduard; Tabarés-Seisdedos, Rafael // BMC Psychiatry;2010, Vol. 10, p47 

    Background: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the...

  • Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Remington, Gary J.; Prendergast, Peter; Bezchlibnyk-Butler, Kalyna Z.; Remington, G J; Prendergast, P; Bezchlibnyk-Butler, K Z // Canadian Journal of Psychiatry;Feb1997, Vol. 42 Issue 1, p53 

    Objective: To evaluate neuroleptic dosing patterns in individuals with schizophrenia over a 10-year interval.Method: Changes in neuroleptic dosing between 1980 and 1990 were followed in 65 patients with a diagnosis of chronic schizophrenia.Results:...

  • Aripiprazole is the STAR for cost effectiveness in schizophrenia.  // PharmacoEconomics & Outcomes News;2/5/2011, Issue 621, p5 

    The article discusses research on the cost effectiveness of aripiprazole in patients with schizophrenia, which references the study "Cost-Effectiveness Analysis of Aripiprazole vs. Standard-of-Care in the Management of Community-Treated Patients With Schizophrenia: STAR Study," by D. King et al,...

  • Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. McKane, J. P.; Robinson, A. D. T.; Wiles, O. H.; McCreadie, R. G.; Stirling, G. S.; Robinson, A D; Wiles, D H // British Journal of Psychiatry;Sep87, Vol. 151, p333 

    In a double-blind study of 38 chronic schizophrenic in-patients, haloperidol decanoate was compared with fluphenazine decanoate as maintenance therapy over 60 weeks. Both drugs were given by injection at 4-week intervals. Haloperidol and fluphenazine were assumed to be equipotent; the mean...

  • First-generation antipsychotics still used in schizophrenia.  // PharmacoEconomics & Outcomes News;3/11/2006, Issue 498, p8 

    Discusses research being done on determinants of first- and second-generation antipsychotic drug use in patients with schizophrenia in European countries. Reference to a study by C. Barbui et al published in the March 2006 issue of "International Clinical Psychopharmacology"; Patients with...

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics. Gruzelier, John; Thornton, Susan; Staniforth, David; Zaki, Saniha; Yorkston, Neil; Gruzelier, J; Thornton, S; Staniforth, D; Zaki, S; Yorkston, N // British Journal of Psychiatry;Aug80, Vol. 137, p131 

    Normal controls and schizophrenic patients on propranolol as sole drug or combined with neuroleptics showed superior active and passive avoidance learning to schizophrenic patients who were medicated with conventional neuroleptics only. Active avoidance involved responding quickly, passive...

  • Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Juckel, Georg; Schlagenhauf, Florian; Koslowski, Michael; Filonov, Dimitri; Wüstenberg, Torsten; Villringer, Arno; Knutson, Brian; Kienast, Thorsten; Gallinat, Jürgen; Wrase, Jana; Heinz, Andreas // Psychopharmacology;Aug2006, Vol. 187 Issue 2, p222 

    Rational Clinical studies in patients with schizophrenia suggest that atypical neuroleptics are more effective than typical neuroleptics in reducing negative symptoms including apathy and anhedonia. Dysfunction of the dopaminergic reward system may contribute to negative symptoms in...

  • Persistent Auditory Hallucinations in Schizophrenia. Buccheri, Robin; Trygstad, Louise; Dowlings, Glenna; Hopkins, Robert; White, Kathleen; Griffin, Jan Johnson; Henderson, Susan; Suciu, Lynda; Hippe, Susan; Kaas, Merrie J.; Covert, Cheryl; Hebert, Patrice // Journal of Psychosocial Nursing & Mental Health Services;Jan2004, Vol. 42 Issue 1, p18 

    The article presents long-term effects of teaching behavioral strategies for managing persistent auditory hallucinations. Auditory hallucinations are common in people with schizophrenia. Although psychotropic medications produce the most potent effect on auditory hallucinations, 25% to 30% of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics